160 related articles for article (PubMed ID: 10434947)
1. Continuous-infusion floxuridine and alpha interferon in metastatic renal cancer: a national biotherapy study group phase II study.
Soori GS; Schulof RS; Stark JJ; Wiemann MC; Honeycutt PJ; Church CK; DePriest CB
Cancer Invest; 1999; 17(6):379-84. PubMed ID: 10434947
[TBL] [Abstract][Full Text] [Related]
2. Treatment of metastatic renal cell carcinoma with constant-rate floxuridine infusion plus recombinant alpha 2b-interferon.
Falcone A; Cianci C; Pfanner E; Ricci S; Lencioni M; Brunetti I; Giulianotti PC; Vannucci L; Mosca F; Conte PF
Ann Oncol; 1996 Aug; 7(6):601-5. PubMed ID: 8879374
[TBL] [Abstract][Full Text] [Related]
3. Alpha-2B-interferon plus floxuridine in metastatic renal cell carcinoma. A phase I-II study.
Falcone A; Cianci C; Ricci S; Brunetti I; Bertuccelli M; Conte PF
Cancer; 1993 Jul; 72(2):564-8. PubMed ID: 8319188
[TBL] [Abstract][Full Text] [Related]
4. Continuous-infusion fluorodeoxyuridine with leucovorin and high-dose interferon: a phase II study in metastatic renal-cell cancer.
Stadler WM; Vogelzang NJ; Vokes EE; Charette J; Whitman G
Cancer Chemother Pharmacol; 1992; 31(3):213-6. PubMed ID: 1464158
[TBL] [Abstract][Full Text] [Related]
5. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
[TBL] [Abstract][Full Text] [Related]
6. Limited efficacy of interferon-alpha and vinblastine as second line biochemotherapy regimen in patients with progressive metastatic renal cell carcinoma.
Lopez Hanninen E; Fenner M; Kirchner H; Deckert M; Duensing S; Menzel T; Poliwoda H; Atzpodien J
Cancer Biother; 1993; 8(4):301-6. PubMed ID: 7804371
[TBL] [Abstract][Full Text] [Related]
7. Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma.
Figlin RA; Belldegrun A; Moldawer N; Zeffren J; deKernion J
J Clin Oncol; 1992 Mar; 10(3):414-21. PubMed ID: 1482425
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, 5-fluorouracil and cis-retinoic acid in the treatment of renal cell carcinoma: final results of cancer biotherapy research group 94-10.
Soori G; Dillman RO; Wiemann MC; Stark JJ; Tai F; DePriest CB; Church CK; Schulof R
Cancer Biother Radiopharm; 2002 Apr; 17(2):165-73. PubMed ID: 12030110
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of subcutaneous interferon followed by intravenous hybrid bolus/continuous infusion interleukin-2 in the treatment of renal cell carcinoma: final results of Cancer Biotherapy Research Group 95-09.
Dillman RO; Wiemann MC; Tai DF; Depriest CB; Soori G; Stark JJ; Mahdavi K; Church CK
Cancer Biother Radiopharm; 2006 Apr; 21(2):130-7. PubMed ID: 16706633
[TBL] [Abstract][Full Text] [Related]
10. An outpatient phase II study of subcutaneous interleukin-2 and interferon-alpha-2b in combination with intravenous vinblastine in metastatic renal cell cancer.
Pectasides D; Varthalitis J; Kostopoulou M; Mylonakis A; Triantaphyllis D; Papadopoulou M; Dimitriadis M; Athanassiou A
Oncology; 1998; 55(1):10-5. PubMed ID: 9428369
[TBL] [Abstract][Full Text] [Related]
11. Infusional floxuridine-based therapy for patients with metastatic renal cell carcinoma.
Reese DM; Corry M; Small EJ
Cancer; 2000 Mar; 88(6):1310-6. PubMed ID: 10717611
[TBL] [Abstract][Full Text] [Related]
12. A multi-institutional phase II trial of a novel inpatient schedule of continuous interleukin-2 with interferon alpha-2b in advanced renal cell carcinoma: major durable responses in a less highly selected patient population.
Clark JI; Kuzel TM; Lestingi TM; Fisher SG; Sorokin P; Martone B; Viola M; Sosman JA
Ann Oncol; 2002 Apr; 13(4):606-13. PubMed ID: 12056712
[TBL] [Abstract][Full Text] [Related]
13. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
Hidalgo OF; AramendÃa JM; Alonso G; Foncillas JG; Brugarolas A
Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
Dutcher JP; Logan T; Gordon M; Sosman J; Weiss G; Margolin K; Plasse T; Mier J; Lotze M; Clark J; Atkins M
Clin Cancer Res; 2000 Sep; 6(9):3442-50. PubMed ID: 10999727
[TBL] [Abstract][Full Text] [Related]
15. A phase I/II study of alternating constant rate infusion floxuridine with constant rate infusion vinblastine for the treatment of metastatic renal cell carcinoma.
Small EJ; Frye JW; Wilkinson MJ; Carroll PR; Ernest ML; Stagg RJ
Cancer; 1994 Jun; 73(11):2803-7. PubMed ID: 8194022
[TBL] [Abstract][Full Text] [Related]
16. A phase I study of recombinant human interleukin-2 and alpha-interferon-2a in patients with renal cell cancer, colorectal cancer, and malignant melanoma.
Mittelman A; Huberman M; Puccio C; Fallon B; Tessitore J; Savona S; Eyre R; Gafney E; Wick M; Skelos A
Cancer; 1990 Aug; 66(4):664-9. PubMed ID: 2386896
[TBL] [Abstract][Full Text] [Related]
17. Inhaled interleukin-2 in combination with low-dose systemic interleukin-2 and interferon alpha in patients with pulmonary metastatic renal-cell carcinoma: effectiveness and toxicity of mainly local treatment.
Huland E; Heinzer H; Huland H
J Cancer Res Clin Oncol; 1994; 120(4):221-8. PubMed ID: 8288676
[TBL] [Abstract][Full Text] [Related]
18. A phase I trial of intermittent high-dose alpha-interferon and dexamethasone in metastatic renal cell carcinoma.
Amato R; Meyers C; Ellerhorst J; Finn L; Kilbourn R; Sella A; Logothetis C
Ann Oncol; 1995 Nov; 6(9):911-4. PubMed ID: 8624294
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of constant-infusion floxuridine for the treatment of metastatic renal cell carcinoma.
Wilkinson MJ; Frye JW; Small EJ; Venook AP; Carroll PR; Ernest ML; Stagg RJ
Cancer; 1993 Jun; 71(11):3601-4. PubMed ID: 8490909
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma.
Clark PE; Hall MC; Miller A; Ridenhour KP; Stindt D; Lovato JF; Patton SE; Brinkley W; Das S; Torti FM
Urology; 2004 Jun; 63(6):1061-5. PubMed ID: 15183950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
